Tenascin C, a glycoprotein pivotal for matrix remodeling, cell adhesion, and survival in the tumor microenvironment, was reduced by 47.5% with KAE and by a stronger 77.9% with cisplatin, a result consistent with efforts to block tumor-stroma interactions and inhibit the supportive niches that foster disease progression. This evidence concerns the gene TNC and neoplasm.